• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用地诺单抗治疗的患者发生颌骨0期骨坏死。

Stage 0 osteonecrosis of the jaw in a patient on denosumab.

作者信息

Aghaloo Tara L, Dry Sarah M, Mallya Sanjay, Tetradis Sotirios

机构信息

Associate Professor, Division of Diagnostic and Surgical Sciences, University of California-Los Angeles School of Dentistry, Los Angeles, CA.

Professor, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at the University of California-Los Angeles, Los Angeles, CA.

出版信息

J Oral Maxillofac Surg. 2014 Apr;72(4):702-16. doi: 10.1016/j.joms.2013.09.008. Epub 2014 Jan 4.

DOI:10.1016/j.joms.2013.09.008
PMID:24397946
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4045108/
Abstract

Osteonecrosis of the jaws (ONJ) is a complex disease involving multiple tissue and cell-type responses to wound healing or infection. AAOMS defines bisphosphonate related ONJ (BRONJ) as exposed, necrotic bone in the maxillofacial region that has persisted for more than 8 weeks in a patient with current or previous antiresorptive treatment, without a history of radiation therapy to the jaws. Since the first reported ONJ cases in 2003 and 2004, there has been little advancement in understanding the etiology and pathophysiology of ONJ. Many hypotheses have been proposed, including bisphosphonate (BP) toxicity to oral epithelium, altered wound healing after tooth extraction, high turnover of the mandible and maxilla, oral biofilm formation, infection and inflammation, and suppression of angiogenesis and bone turnover. The current classification system of ONJ involves stages 0 to 3 and is based on patient clinical presentation. This report describes a case of stage 0 ONJ in a patient on denosumab and indicates the full-spectrum similarities between BP- and denosumab-associated ONJ clinically, radiographically, and histologically.

摘要

颌骨骨坏死(ONJ)是一种复杂的疾病,涉及多种组织和细胞类型对伤口愈合或感染的反应。美国口腔颌面外科医师协会(AAOMS)将双膦酸盐相关颌骨骨坏死(BRONJ)定义为:在接受过当前或既往抗吸收治疗的患者中,颌面部区域暴露的坏死骨持续超过8周,且无颌骨放射治疗史。自2003年和2004年首次报道ONJ病例以来,在理解ONJ的病因和病理生理学方面进展甚微。已经提出了许多假说,包括双膦酸盐(BP)对口腔上皮的毒性、拔牙后伤口愈合改变、下颌骨和上颌骨的高周转率、口腔生物膜形成、感染和炎症,以及血管生成和骨转换的抑制。目前ONJ的分类系统包括0至3期,基于患者的临床表现。本报告描述了1例使用地诺单抗的患者发生0期ONJ的病例,并指出了BP相关和地诺单抗相关ONJ在临床、影像学和组织学上的全面相似性。

相似文献

1
Stage 0 osteonecrosis of the jaw in a patient on denosumab.使用地诺单抗治疗的患者发生颌骨0期骨坏死。
J Oral Maxillofac Surg. 2014 Apr;72(4):702-16. doi: 10.1016/j.joms.2013.09.008. Epub 2014 Jan 4.
2
Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases.地诺单抗与颌骨坏死——药理学、发病机制及两例报告
Aust Dent J. 2014 Dec;59(4):516-9. doi: 10.1111/adj.12217. Epub 2014 Sep 27.
3
Denosumab-associated osteonecrosis of the jaw--a case report.地诺单抗相关性颌骨坏死——病例报告
Dent Update. 2014 Jun;41(5):449-50. doi: 10.12968/denu.2014.41.5.449.
4
Denosumab-related osteonecrosis of the jaw.地舒单抗相关性颌骨坏死。
J Am Dent Assoc. 2012 Sep;143(9):981-4. doi: 10.14219/jada.archive.2012.0323.
5
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.颌骨骨坏死的诊断和治疗:系统评价和国际共识。
J Bone Miner Res. 2015 Jan;30(1):3-23. doi: 10.1002/jbmr.2405.
6
Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.抗吸收药物对颌骨骨转换的影响:地诺单抗与双膦酸盐的比较。
Br J Oral Maxillofac Surg. 2014 Apr;52(4):308-13. doi: 10.1016/j.bjoms.2014.01.021. Epub 2014 Feb 26.
7
Osteonecrosis of the jaw in a patient on Denosumab.使用地诺单抗治疗的患者发生颌骨坏死。
J Oral Maxillofac Surg. 2010 May;68(5):959-63. doi: 10.1016/j.joms.2009.10.010. Epub 2010 Feb 10.
8
Antiresorptive drug-related osteonecrosis of the jaw.抗吸收药物相关的颌骨坏死
Dent Clin North Am. 2014 Apr;58(2):369-84. doi: 10.1016/j.cden.2013.12.006.
9
Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab.接受地舒单抗治疗的男性骨质疏松症患者发生下颌骨坏死。
Osteoporos Int. 2014 Jan;25(1):393-5. doi: 10.1007/s00198-013-2437-z. Epub 2013 Jul 9.
10
Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection.成功手术治疗 RANK 配体抑制剂治疗导致的颌骨骨坏死:荧光引导骨切除术。
J Craniomaxillofac Surg. 2013 Oct;41(7):694-8. doi: 10.1016/j.jcms.2013.05.038. Epub 2013 Jul 5.

引用本文的文献

1
Three-dimensional clinical assessment for MRONJ risk in oncologic patients following tooth extractions.三维临床评估在肿瘤患者拔牙后 MRONJ 风险中的应用。
Dentomaxillofac Radiol. 2023 Nov;52(8):20230238. doi: 10.1259/dmfr.20230238. Epub 2023 Oct 24.
2
Histopathological significance of necrosis in oral lesions: A review.口腔病变中坏死的组织病理学意义:综述
J Oral Maxillofac Pathol. 2023 Apr-Jun;27(2):340-347. doi: 10.4103/jomfp.jomfp_39_23. Epub 2023 Jul 13.
3
Osteonecrosis of the Jaw.颌骨骨坏死

本文引用的文献

1
Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab.接受地舒单抗治疗的男性骨质疏松症患者发生下颌骨坏死。
Osteoporos Int. 2014 Jan;25(1):393-5. doi: 10.1007/s00198-013-2437-z. Epub 2013 Jul 9.
2
Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice.根尖周病和双膦酸盐可诱导小鼠颌骨坏死。
J Bone Miner Res. 2013 Jul;28(7):1631-40. doi: 10.1002/jbmr.1894.
3
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.双膦酸盐治疗骨质疏松症:获益、风险和药物假期。
Dent J (Basel). 2023 Jan 9;11(1):23. doi: 10.3390/dj11010023.
4
Radiographic predictors for MRONJ in oncologic patients undergoing tooth extraction.接受拔牙治疗的肿瘤患者中放射性颌骨骨坏死的影像学预测因子。
Sci Rep. 2022 Jul 4;12(1):11280. doi: 10.1038/s41598-022-15254-y.
5
Inhibition of HMGB1/RAGE Signaling Reduces the Incidence of Medication-Related Osteonecrosis of the Jaw (MRONJ) in Mice.HMGB1/RAGE 信号通路抑制可降低小鼠药物相关性颌骨坏死(MRONJ)的发生率。
J Bone Miner Res. 2022 Sep;37(9):1775-1786. doi: 10.1002/jbmr.4637. Epub 2022 Jul 11.
6
Nonexposed antiresorptive agent-related osteomyelitis of the jaw: a single-center cohort study.非暴露性抗吸收剂相关性颌骨骨髓炎:一项单中心队列研究。
J Bone Miner Metab. 2022 Jul;40(4):657-662. doi: 10.1007/s00774-022-01329-3. Epub 2022 May 9.
7
Local RANKL delivery improves socket healing in bisphosphonate treated rats.局部 RANKL 递送可改善双膦酸盐治疗大鼠的 socket 愈合。
Bone. 2021 Jul;148:115945. doi: 10.1016/j.bone.2021.115945. Epub 2021 Apr 7.
8
Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw? A review.各种影像学方法能否提供药物相关性颌骨坏死的潜在早期检测和诊断?综述。
Dentomaxillofac Radiol. 2021 Sep 1;50(6):20200417. doi: 10.1259/dmfr.20200417. Epub 2021 Jan 15.
9
Denosumab for Effective Tumor Size Reduction in Patients With Giant Cell Tumors of the Bone: A Systematic Review and Meta-Analysis.地舒单抗治疗骨巨细胞瘤患者的肿瘤有效缩小:系统评价和荟萃分析。
Cancer Control. 2020 Jul-Aug;27(3):1073274820934822. doi: 10.1177/1073274820934822.
10
Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice.唑来膦酸治疗小鼠牙槽骨骨坏死中,挽救性双膦酸盐治疗可改善拔牙窝愈合。
Bone. 2019 Jun;123:115-128. doi: 10.1016/j.bone.2019.03.027. Epub 2019 Mar 26.
Am J Med. 2013 Jan;126(1):13-20. doi: 10.1016/j.amjmed.2012.06.023. Epub 2012 Nov 20.
4
Histopathological features of bisphosphonate-associated osteonecrosis: findings in patients treated with partial mandibulectomies.双膦酸盐相关性骨坏死的组织病理学特征:接受下颌部分切除术治疗患者的发现。
Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Dec;114(6):785-91. doi: 10.1016/j.oooo.2012.08.457.
5
Antiresorptives and osteonecrosis of the jaw.抗吸收药物与颌骨坏死。
J Evid Based Dent Pract. 2012 Sep;12(3 Suppl):233-47. doi: 10.1016/S1532-3382(12)70046-5.
6
Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis.唑来膦酸的肿瘤剂量会导致伴牙周炎的田鼠(Oryzomys palustris)出现类似下颌骨坏死的病变。
J Bone Miner Res. 2012 Oct;27(10):2130-43. doi: 10.1002/jbmr.1669.
7
Bisphosphonate related osteonecrosis of the jaw: A minipig large animal model.双膦酸盐相关性颌骨坏死:小型猪大动物模型。
Bone. 2012 Sep;51(3):592-9. doi: 10.1016/j.bone.2012.04.020. Epub 2012 May 7.
8
Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain.口腔颌骨部位的双膦酸盐相关性骨坏死:西班牙 20 例系列病例的临床特征。
Med Oral Patol Oral Cir Bucal. 2012 Sep 1;17(5):e751-8. doi: 10.4317/medoral.18041.
9
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.从实验室到临床:OPG-RANK-RANKL 通路的阐明和地舒单抗的研发。
Nat Rev Drug Discov. 2012 May;11(5):401-19. doi: 10.1038/nrd3705.
10
Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients.解读肿瘤临床试验结果:地舒单抗与唑来膦酸预防癌症患者骨骼相关事件的比较。
Support Care Cancer. 2012 Jul;20(7):1353-60. doi: 10.1007/s00520-012-1461-4. Epub 2012 Apr 27.